Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy.
about
KASL clinical practice guidelines: management of chronic hepatitis BGenetic variation of hepatitis B virus and its significance for pathogenesisClinical impact of occult hepatitis B virus infection in immunosuppressed patientsLack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasisDetection of HBV genotypes of tumor tissues and serum by a fluorescence polarization assay in north-western China's hepatocellular carcinoma patients.The Impact of Chemotherapy on Hepatitis B Antibody Titer in Patients with Hematological Malignancies.KASL Clinical Practice Guidelines: Management of chronic hepatitis B.Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective studyIncidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt.Severe de novo Hepatitis B Recovered from Late-Onset Liver Insufficiency with Prolonged Ascites and Hypoalbuminemia due to Hepatitis B Virus Genotype Bj with Precore Mutation.Rituximab for the treatment of rheumatoid arthritis: an update.Characteristics of escape mutations from occult hepatitis B virus infected patients with hematological malignancies in South Egypt.Patients with hematological malignancies and serological signs of prior resolved hepatitis B.The prevalence and long term outcome of occult hepatitis B virus infections in community based populations.Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab.Antiviral therapies for managing viral hepatitis in lymphoma patients.Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience.Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection.Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.Kinetics of peripheral hepatitis B virus-specific CD8+ T cells in patients with onset of viral reactivation.Reduced therapeutic effect of antiviral drugs in patients with hepatitis B virus reactivation after hematopoietic stem cell transplantation.HBV-related events after allogeneic hematopoetic stem cell transplantatıon in a center from Turkey.Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review.Hepatitis B Virus Adaptation to the CD8+ T Cell Response: Consequences for Host and PathogenA novel stop codon mutation within the hepatitis B surface gene is detected in the liver but not in the peripheral blood mononuclear cells of HIV-infected individuals with occult HBV infection
P2860
Q26752475-211A9943-6842-4A89-9B96-3BAAC21C24D8Q26772348-AB64DE34-1637-42CB-B77A-9964347CCF34Q27006996-FB275981-9BF3-4E89-91AE-9B5A734F6B3AQ34786720-FDA567DC-73D7-4E92-AC82-0AC70E5A5597Q35154962-97F4514F-9621-46F3-A81F-ADB631B7656FQ36038914-AC332095-33D2-4FEF-9103-16BB50EDEAABQ36153966-544549F7-91A2-4D9F-A836-75497ED5A031Q36616847-8283156B-B21B-4ADC-8561-B67C0D51BF85Q37208128-4D3118EC-857B-4B8A-AE00-E0B281A9AA87Q37434926-88A0A552-4FC0-44DE-BF23-1D8212A9A628Q37444678-E5195537-ED25-4CE7-BCA9-F07360E79E41Q37723981-6F538E28-6D82-4612-A186-F2185D031042Q37999022-7655D33D-EA38-4812-A14F-F495CEBCEE2DQ38028865-64CE6185-3C4F-4282-9A78-879852D9960BQ38218566-D53CB5D3-1FD4-4EAB-9182-22DE9EF5BA59Q38253568-A720A154-EA89-4609-BEBB-5CD9D8B5E24BQ38989625-334F6FCF-919A-4A8B-8139-1F31FA37FA7EQ40484172-2F68BB85-2305-400F-BF97-84617067C964Q41482859-A413E98B-097E-4FC8-BD92-A61EA09C512BQ41526311-8539D8D9-3287-45B0-9250-9B5D49E4001BQ42278229-250A85D0-DECA-4F9D-8378-495805FABDC3Q44218960-723CC33C-A152-4751-9510-46AC004172E5Q47566400-4EC420A8-6C3C-4F6A-A4E4-ACD6443584D2Q51297254-2FC659F6-B99F-4F65-A6F0-9F6CD3B085B9Q55487854-AD1F68C8-78F4-4718-95DF-4BF609DE2D6CQ56918262-F8D4662F-4936-432D-977B-A49C898F09CBQ56979536-03D6FA0F-2052-43F1-B457-C7EAE6B02769
P2860
Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Virological and clinical chara ...... with hematological malignancy.
@en
Virological and clinical chara ...... with hematological malignancy.
@nl
type
label
Virological and clinical chara ...... with hematological malignancy.
@en
Virological and clinical chara ...... with hematological malignancy.
@nl
prefLabel
Virological and clinical chara ...... with hematological malignancy.
@en
Virological and clinical chara ...... with hematological malignancy.
@nl
P2093
P2860
P356
P1476
Virological and clinical chara ...... with hematological malignancy.
@en
P2093
Fuat Kurbanov
Fuminaka Sugauchi
Kentaro Matsuura
Masashi Mizokami
Masaya Sugiyama
Ryuzo Ueda
Shigeru Kusumoto
Yasuhito Tanaka
P2860
P304
P356
10.1002/JMV.21995
P577
2011-03-01T00:00:00Z